CTOR Citius Oncology, Inc. Operating Profitability

Corporate company logo of citiusonc.com (CTOR)

The operating margin metric demonstrates the efficiency dynamics of Citius Oncology, Inc. (CTOR), where -665.60 is the current value of the indicator. Citius Oncology, Inc. (CTOR) minimizes capital expenditures by outsourcing production and testing to external partners. Specialization in rare lymphatic pathologies and orphan drug status protect the niche from replication. Current revenue is generated by the market launch of a treatment for cutaneous T-cell lymphoma.

CTOR - Citius Oncology Operating Profit Rate over the range 08/14/2024 - 11/20/2026

Analytical breakdowns for Citius Oncology, Inc. (CTOR)

Comprehensive company analysis:CTOR, citiusonc.com
Core merchandise of Citius Oncology Inc

Operating margin reflects the share of profit from core operations relative to total revenue. This indicator measures cost management efficiency before accounting for taxes and debt obligations. For Citius Oncology, Inc. (CTOR), the absence of proprietary manufacturing plants and the outsourcing of trials minimize capital expenditures, directly impacting the calculation of this metric. The trend in operational efficiency allows for an assessment of the profitability of such a flexible business model. An increase in this indicator confirms the company's stability.

Competitors of Citius Oncology, Inc.

Operating Profitability BeiGene Ltd|Halozyme Therapeutics - Operating Profit Margin|Operating Sales Margin RVMD (Revolution Medicines Corp)|Operating Profit Ratio AAPG|Operating Profitability CG Oncology Therapeutics CGON|Operating Profit Rate URGN|BCAX: Operating Sales Margin|PSNL: Operating Profitability|Erasca (ERAS) - Operating Profitability|DCTH - Profitability of Operations|YMAB (Y-mAbs Corp) - Operating Margin|Operating Sales Margin Aura Biosciences (AURA)|Operating Profitability Candel Therapeutics Inc. (CADL)|Operating Sales Margin Accuray, Inc. ARAY|Operating Profitability sellaslifesciences.com SLS|Operating Profit Rate ACTU|TuHURA Biosciences Inc. - Operating Margin|TARA - Operating Margin|FATE (Fate Therapeutics) - Operating Sales Margin|Operating Sales Margin Aadi Bioscience, Inc.|Operating Sales Margin TCRX|Operating Profitability CSBR|Operating Margin XBIT|Profitability of Operations CEL-SCI Corp.|Operating Profitability ostherapies.com OSTX|RADX: Return on Sales by Operating Profit|ARTV: Operating Sales Margin|ANL (Adlai Nortye) - Return on Sales by Operating Profit|Veru (VERU) - Operating Profitability|Operating Sales Margin Tempest Therapeutics Inc|Operating Profitability Xilio Therapeutics|Return on Sales by Operating Profit RENB (Renovaro Inc.)|Operating Profitability Mural Oncology PLC (MURA)|Operating Margin Kairos Pharma (KAPA)|Operating Profitability onkuretherapeutics.com OKUR|GDTC: Return on Sales by Operating Profit|CRIS: Operating Sales Margin|apollomicsinc.com (APLM) - Operating Sales Margin|THAR: Operating Margin|Operating Sales Margin Advanced Biomed Inc.|Operating Sales Margin GNPX|Return on Sales by Operating Profit CLDI (Calidi Biotherapeutics)|Operating Margin SBFM|Xenetic Biosciences, Inc. - Return on Sales by Operating Profit|Operating Profitability Salarius Pharmaceuticals SLRX|Operating Margin purple-biotech.com PPBT|AONC - Operating Profitability|BGNE: Operating Profitability|CKPT: Operating Margin|Elevation Oncology - Operating Profit Rate|ICAD (iCAD) - Operating Margin|IKNA: Operating Profit Rate|Operating Profitability Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Operating Profit Rate|Operating Profitability MorphoSys Corporation MOR|NAYA: Return on Sales by Operating Profit|Ascentage Pharma Group International - Operating Margin